For decades, the way Americans get prescription drugs has followed a rigid and opaque path. Drugmakers sell to wholesalers. Pharmacy benefit managers negotiate rebates. Insurers design formularies. Employers buy coverage. Patients hope the drug they need makes it through the maze.

But obesity medicines are starting to shake that system.

A Different Option for Employers

Recently, Eli Lilly and Company announced a new approach to make its obesity medicine Zepbound easier for employers to cover. Instead of relying entirely on the traditional pharmacy benefit system, the company is offering a program that allows employers to provide access at a predictable monthly cost. In effect, it shortens the supply chain between the drugmaker, the employer, and the patient.

That may sound like a technical tweak. In reality, it could mark a much bigger shift.

Pushing PBMs to Change

For years, pharmacy benefit managers — notably CVS Health, UnitedHealth Group, and Cigna — have played a central role in determining which drugs people can access and at what price. Their business models depend heavily on complex rebate arrangements and opaque pricing structures. But growing regulatory scrutiny and employer frustration are pushing that system to evolve.

Obesity medicines are accelerating the change.

Demand is enormous. Patients want access. Employers increasingly see obesity treatment as important for health and productivity. Yet many insurance plans still exclude these medicines because of their potential cost.

Questioning a Broken System

When a manufacturer offers a clear, predictable price outside the traditional benefit structure, it forces employers to ask a simple question: is the old system actually helping us meet the needs of our employees?

That question could have consequences far beyond obesity care.

If direct arrangements between drugmakers, employers, and patients expand, the prescription drug market may become more responsive to real human needs instead of the incentives embedded in a complex chain of intermediaries.

Obesity medicines might not just change health outcomes. They may also change the system that delivers the treatments people need.

Click here for more on Lilly’s employer connect program and here for more on how PBMs are scrambling to adapt.

A Model Pharmacy Shattered, adapted from a photograph by Harrison Keely, licensed under CC BY 4.0